KA-3003 / KYinno - LARVOL DELTA

The triple-specific antibody KA-3003, targeting PSMA, CD28, and 4-1BB, is developed for the treatment of prostate cancer by enhancing T cell activity within the tumor (AACR 2024) - "KA-3003 shows neither aggregation nor degradation. In conclusion, the tri-specific antibody KA-3003, developed with our common light chain antibody discovery platform, stands out as a promising pre-clinical candidate drug for the treatment of prostate cancer."

IO biomarker • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • TNFRSF9